Intratumoral estrogen disposition in breast cancer

Clinical Cancer Research

Volumn 16, Issue 6, 2010, Pages 1790-1801

  Haynes, Ben P ^a   Straume, Anne Hege ^b,c   Geisler, Jürgen ^d   A'Hern, Roger ^e   Helle, Hildegunn ^c   Smith, Ian E ^a   Lønning, Per E ^b,c   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTRADIOL; ESTRADIOL RECEPTOR; ESTROGEN RECEPTOR; ESTRONE; HSD17B1 PROTEIN; HSD17B12 PROTEIN; HSD17B7 PROTEIN; HYDROXYSTEROID DEHYDROGENASE; SULFATASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CASE CONTROL STUDY; CONTROLLED STUDY; DOWN REGULATION; ESTRADIOL BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TISSUE LEVEL; UPREGULATION;

3-HYDROXYSTEROID DEHYDROGENASES; ADULT; AGED; AGED, 80 AND OVER; AROMATASE; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; ESTRONE; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFOTRANSFERASES;

EID: 77949752567     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2481     Document Type: Article

References (45)

1. Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
2. Geisler J, Lønning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 2005;11:2809-21.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
4. Lønning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990; 35:355-66.
5. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42.
6. Van Landeghem AAJ, Poortman J, Nabuurs M, Thijssen JHH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res 1985;45:2900-4.
7. Miller WR. Importance of intratumour aromatase, and its susceptibility to inhibitors. In: Dowsett M, editor. Aromatase inhibition - then, now and tomorrow. London: Parthenon Publishing Group; 1994, p. 43-53.
8. Santner SJ, Feil PD, Santen RJ. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 1984;59: 29-33.
9. Gunnarsson C, Hellqvist E, Stål O. 17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer 2005;92:547-52.
10. Masamura S, Santner SJ, Gimotty P, George J, Santen RJ. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 1997;42:215-26.
11. James VHT, Reed MJ, Adams EF, et al. Oestrogen uptake and metabolism in vivo. In: Beck JS, editor. Oestrogens and the human breast. Proc Roy Soc Edinb 1989;95B:185-93.
12. O'Neill JS, Elton RA, Miller WR. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J 1988;296: 741-3.
13. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993;77:1622-8.
14. Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G, Dixon JM. An integrated view of aromatase and its inhibition. J Steroid Biochem Mol Biol 2003;86:413-21.
15. Ellis MJ, Miller WR, Tao Y, et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat 2009;116:371-8.
16. Reed MJ, Purohit A. Sulphatase inhibitors: the rationale for the development of a new endocrine therapy. Rev Endocr Rel Cancer 1993; 45:51-62.
17. Lønning PE, Johannessen DC, Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer 1989;60:107-11.
18. Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada NJ. Elevated steroid sulfatase expression in breast cancers. Steroid Biochem Mol Biol 2000;73:141-5.
19. Miyoshi Y, Ando A, Hasegawa S, et al. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 2003;9:2288-93.
20. Poutanen M, Miettinen M, Vihko R. Differential estrogen substrate specificities for transiently expressed human placental 17β-hydroxysteroid dehydrogenase and an endogenous enzyme expressed in cultured COS-m6 cells. Endocrinology 1993;133:2639-44.
21. Penning TM, Burczynski ME, Jez JM, et al. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;351:67-77.
22. Krazeisen A, Breitling R, Imai K, Fritz S, Möller G, Adamski J. Determination of cDNA, gene structure and chromosomal localization of the novel human 17β-hydroxysteroid dehydrogenase type 7. FEBS Lett 1999;460:373-9.
23. Luu-The V, Tremblay P, Labrie F. Characterization of type 12 17β-hydroxysteroid dehydrogenase, an isoform of type 3 17β- hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol 2006;20:437-43.
24. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S. Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 α-hydroxysteroid dehydrogenase activity. J Biol Chem 1993;268: 12964-9.
25. He XY, Wegiel J, Yang YZ, Pullarkat R, Schulz H, Yang SY. Type 10 17β-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of γ-aminobutyric acid type A receptors. Mol Cell Endocrinol 2005;229:111-7.
26. Lukacik P, Keller B, Bunkoczi G, et al. Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. Biochem J 2007;402: 419-27.
27. McNeill JM, Reed MJ, Beranek PA, et al. A comparison of the in vivo uptake and metabolism of 3H-oestrone and 3H-oestradiol by normal breast and breast tumour tissue in postmenopausal women. Int J Cancer 1986;38:205-12.
28. Haynes B, Ghazoui Z, Anderson H, et al. Identification of molecular predictors of response of advanced breast cancer patients to aromatase inhibition. Breast Cancer Res Treat 2008;106:S93.
29. Blankenstein MA, Maitimu-Smeele I, Donker GH, Daroszewski J, Milewicz A, Thijssen JHH. On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 1992;41:891-6.
30. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 2000;2:23-7.
31. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7:1230-6.
32. Geisler J, Helle H, Ekse D, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 2008;14:6330-5.
33. Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009;117:31-41.
34. Geisler J, Berntsen H, Lønning P. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J Steroid Biochem Molec Biol 2000;72: 259-64.
35. Geisler J, Ekse D, Helle H, Duong NK, Lønning PE. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 2008;109: 90-5.
36. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30.
37. Kruchten P, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW. Development of a biological screening system for the evaluation of highly active and selective 17β-HSD1-inhibitors as potential therapeutic agents. Mol Cell Endocrinol 2009;301:154-7.
38. Lawrence HR, Vicker N, Allan GM, et al. Novel and potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem 2005;48: 2759-62.
39. Day JM, Purohit A, Tutill HJ, et al. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann N Y Acad Sci 2009;1155:80-7.
40. Dunbier AK, Anderson H, Ghazoui Z, et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol Epub 2010 Feb 1. PubMed PMID: 20124184.
41. Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stål O. 17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res 2006;66:11471-7.
42. Suzuki M, Ishida H, Shiotsu Y, et al. Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients. J Steroid Biochem Mol Biol 2009; 113:195-201.
43. Han B, Li S, Song D, et al. Expression of 17β-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. J Steroid Biochem Mol Biol 2008;112:194-200.
44. Honma N, Takubo K, Sawabe M, et al. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J Clin Endocrinol Metab 2006;91:607-13.
45. Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolizing enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 2006;99:275-88.